Q1FY2025 Performance Highlights Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264bps YoY to 61.3% EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%, a growth of 187bps YoY US revenues at a historic
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation Approval bolsters Strides’ portfolio for the US by adding another differentiated and niche product with limited competition Strides Pharma Science Limited (Strides) today announced that its step-down wholly
